# Stämm

> Stämm is a deep-tech biomanufacturing company building a desktop-scale, 3D-printed, bubble-free bioprocessor that replaces the giant stainless-steel tanks of conventional pharma. Founded in Buenos Aires and headquartered in San Francisco, the company is pursuing a vision of decentralized, AI-driven production of biologics and cell therapies.

- **Founded:** 2013
- **Headquarters:** San Francisco, United States
- **Founders:** Juan "Yuyo" Llamazares Vegh (Co-Founder & CEO), Federico D'Alvia Vegh (Co-Founder)
- **Team size:** 200+ collaborators
- **Products:** High-Throughput Bioprocessor (HTB), Bubble-Free Bioreactor (BFB), Cell Line Development, Bio AI Platform
- **Notable:** Demonstrated up to 30x antibody productivity vs. traditional stirred-tank bioreactors in pilots., Subject of a Harvard Business School case study on biomanufacturing decentralization., Launched the High-Throughput Bioprocessor with its Bubble-Free Bioreactor in 2026.

## Products & services

- **High-Throughput Bioprocessor (HTB)** — An automated, single-use biomanufacturing platform for adherent and suspension cells, available for Research Use Only.
- **Bubble-Free Bioreactor (BFB)** — A 3D-printed, customizable consumable at the heart of the HTB that eliminates the traditional impeller and the shear stress that comes with it.
- **Cell Line Development** — End-to-end clone selection and stable cell line services for clinical and commercial manufacturing.
- **Bio AI Platform** — Generative-model-based platform for multi-omics analysis and simulation of cellular biomolecular behavior.

## Achievements

- Demonstrated up to 30x antibody productivity vs. traditional stirred-tank bioreactors in pilots.
- Subject of a Harvard Business School case study on biomanufacturing decentralization.
- Launched the High-Throughput Bioprocessor with its Bubble-Free Bioreactor in 2026.
- Opened R&D operations across three continents - Buenos Aires, San Francisco, and Monthey.

## Latest updates

- **2026-03** — Launched the High-Throughput Bioprocessor (HTB) with the Bubble-Free Bioreactor, available for Research Use Only.
- **2024** — Opened R&D facilities at BioArk in Monthey, Switzerland and closed Series B financing.
- **2023** — Bioprocessor prototypes validated at BioArk, Switzerland.

## Links

- Website: https://stamm.bio
- LinkedIn: https://www.linkedin.com/company/stammbio
- Twitter/X: https://twitter.com/stammbio
- Instagram: https://www.instagram.com/stamm.bio/

---

Profile page: https://yespress.io/st-mm
Published by YesPress — https://yespress.io
Last updated: 2026-05-23